- Research category
- GLP-1 / Weight Management
- Format
- Lyophilized peptide material
- Purity spec
- Greater than 99%
- Availability
- Approved accounts
- Documentation
- COA coming soon
Certificate of Analysis coming soon
GLP-1 / Weight Management
Tirzepatide
Dual GIP and GLP-1 receptor agonist. The compendium notes the same active compound as Mounjaro and Zepbound and positions GIP activation as an enhancer of fat metabolism beyond GLP-1 alone. Mechanism: GLP-1 reduces appetite, slows gastric emptying, and stimulates insulin. GIP enhances fat metabolism and energy regulation.
- Availability
- Wholesale Access Only
Tirzepatide · Research use only
Research context
Weight management programs; metabolic syndrome; body composition optimization; plateau after semaglutide.
Material information
- Grade
- Research Use Only (RUO)
- Format
- Lyophilized peptide material
- Purity
- Greater than 99%
- Appearance
- Lyophilized powder
Documentation
Batch-specific documentation may be available for approved account review. View documentation standards.
Regulatory status
For laboratory research use only. Not for human consumption, diagnosis, treatment, cure, or prevention of disease.
Restrictions
Research use only
This material is offered for research use only. Not for human or animal use. Not intended for clinical, diagnostic, therapeutic, veterinary, or personal use. PeptaPharma does not provide dosing, administration, or treatment guidance.
Related materials
Synthesized & tested in the United States.
PeptaPharma materials are produced and analytically tested in U.S. facilities. Batch-level documentation and Certificates of Analysis accompany each lot for approved-account review.